An FDA-approved migraine medication may hold the key to repairing broken circadian clocks. A computational screening study published this week in Molecular Diversity identifies dihydroergotamine (DHE) as a promising candidate for reversing the physiological damage caused by circadian disruption. In sleep-deprived mice, the drug restored weight stability, rescued recognition memory, and normalized sleep architecture through a mechanism that appears to involve the core clock protein CRY1.
The findings come from a team led by Linhui Cai and Yixin Sun at Xiamen University in China. They represent a novel entry in the growing field of chronotherapy, where existing drugs are being evaluated for their ability to directly modulate the molecular machinery of the body’s internal timekeeping system.
The virtual screening
The researchers began with a multi-scale computational screen of 1,429 FDA-approved small molecules. These compounds were docked against five key circadian proteins: CLOCK, BMAL1, PER1, PER2, and CRY1. The goal was to identify molecules with a high predicted affinity for any of these targets, potentially allowing them to stabilize or restore circadian function.
The team applied the TOPSIS algorithm, a multi-criteria decision analysis tool, to rank candidates across several dimensions of predicted performance. They also incorporated a machine learning model to assess each compound’s likely impact on gut microbiota, an increasingly recognized modulator of circadian biology.
Dihydroergotamine emerged as the top overall candidate. The drug, a vasoconstrictor used for decades in migraine and cluster headache treatment, showed strong predicted binding to the CRY1 protein. To test the stability of this interaction, the team ran a 100-nanosecond molecular dynamics simulation. The DHE-CRY1 complex remained stable throughout the simulation, supporting the hypothesis of a genuine binding interaction.
The in vivo validation
The study then moved from computation to live animals. Mice subjected to sleep deprivation developed the expected hallmarks of circadian disruption: weight loss, impaired recognition memory, and fragmented sleep architecture with altered ratios of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep.
Administration of DHE reversed all three of these deficits. Treated mice regained body weight, performed significantly better on memory tasks, and recovered a normal sleep structure. The drug appeared to act by promoting the nuclear accumulation of the PER1-CRY1 protein complex. This in turn suppressed CLOCK expression, effectively resetting the transcriptional feedback loop that governs the circadian cycle.
These results suggest that DHE does not simply mask the symptoms of circadian disruption but may intervene at the level of the molecular clock itself.
Why it matters
Circadian disruption is a pervasive feature of modern life. Shift work, jet lag, chronic sleep restriction, and certain neuropsychiatric conditions all disturb the body’s internal rhythms. The resulting dysregulation has been linked to metabolic disease, cognitive decline, cardiovascular risk, and mood disorders.
Current options for correcting circadian misalignment are limited to behavioral interventions, melatonin supplementation, and light therapy. A small-molecule drug that directly targets a core clock protein would represent a fundamentally different approach. Because DHE is already approved for human use, the path to clinical testing could be considerably shorter than for a novel compound.
Limits
The central limitation of this study is that the DHE-CRY1 interaction remains computationally predicted. No experimental binding assay, such as surface plasmon resonance or isothermal titration calorimetry, has yet confirmed that the drug physically binds the protein. The behavioral and physiological effects observed in mice may involve additional targets or indirect pathways that the computational screen did not capture.
The study was also conducted entirely in rodents. Whether the effects translate to humans, and at what dose, remain open questions. DHE is a potent vasoconstrictor with a narrow therapeutic window, and its safety profile in a sleep-disrupted population would need careful evaluation.
Bottom line
A computational screen of FDA-approved drugs has identified dihydroergotamine as a candidate for reversing circadian disruption through predicted CRY1 binding. In mice, the drug corrected weight loss, memory impairment, and sleep architecture changes caused by sleep deprivation. Experimental confirmation of the DHE-CRY1 interaction is needed before the mechanism can be considered validated, but the findings open a new avenue in the search for pharmacological circadian modulators.
Source
Cai L, Sun Y, et al. Identification of dihydroergotamine as a circadian rhythm regulator through multi-scale virtual screening and experimental validation in sleep-deprived mice. Molecular Diversity. Published online July 9, 2026. DOI: 10.1007/s11030-026-11652-w. PMID: 42423922.